Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives.
Radiolabeled cyclic peptides are taking center stage in precision oncology. The latest review in J Control Release breaks down why these research peptides are getting so much attention from nuclear medicine teams. They aren’t just a cool side project — they’re helping push theranostics into the mainstream and changing how researchers target tumors.
J Control Release
by Ai D, Li J, Shi J et al.
“Radiolabeled cyclic peptides in precision oncology: Current advances and future perspectives. Ai D(1), Li J(2), Shi J(1), Sang S(1), Zhang B(1), Ge S(3), Deng S(4). Author information: (1)Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. (2)Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, Jiangsu, China. (3)Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, Jiangsu, China. Electronic address: geshushan0820@163.com. (4)Department of Nuclear Medicine, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Electronic address: dshming@163.com. In recent years, the regulatory approval of radiopharmaceuticals such as [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617, alongside their diagnostic counterparts [68Ga]Ga-DOTATATE and [68Ga]Ga-PSMA-11, has propelled theranostics into the clinical mainstream, marking a transformative shift in nuclear medicine and precision oncology. Amid this dynamic progress, cyclic peptides have emerged as indispensable vectors for targeted delivery in nuclear medicine, owing to their exceptional resistance to enzymatic degradation, superior conformational stability, and high receptor-binding affinity. These properties endow radiolabeled cyclic peptides with favorable pharmacokinetics, elevated tumor accumulation, and excellent target-to-background contrast, features that have enabled their widespread application in imaging and therapy targeting somatostatin receptors, integrins, FAP, PD-L1, and other tumor-associated biomarkers. With their molecular precision, structural versatility, and therapeutic adaptability, cyclic peptides are positioned at the forefront of next-generation radiopharmaceutical development. As the field continues to evolve toward increasingly personalized and molecularly targeted cancer therapies, radiolabeled cyclic peptides are poised to play a pivotal role in redefining the future landscape of radiotherapy. Copyright © 2026. Published by Elsevier B.V. Conflict of interest statement: Declaration of competing interest The authors declare no competing interests.”
The science comes down to three things: stability, specificity, and strong receptor binding. Cyclic peptides are less likely to break down in the body. Their structures hold up under pressure, and they latch onto tumor markers with impressive accuracy. That makes them ideal for delivering radiolabels where they need to go — right into the tumor, not scattered everywhere else.
Key takeaway: Radiolabeled cyclic peptides are showing up in both imaging and therapy. Researchers are using them to zero in on targets like somatostatin receptors, integrins, FAP, and PD-L1. The results? High tumor uptake and sharp contrast, making it easier to see and treat cancer.
Here’s what’s driving the buzz:
Regulatory green lights for radiopharmaceuticals like [177Lu]Lu-DOTATATE and [177Lu]Lu-PSMA-617
Diagnostic tools ([68Ga]Ga-DOTATATE, [68Ga]Ga-PSMA-11) are already clinical workhorses
Cyclic peptides offer a versatile scaffold for tuning targeting and delivery
As researchers push cancer therapies toward more personal, molecularly guided strategies, radiolabeled cyclic peptides are leading the charge. The field is wide open for new peptide designs and smarter delivery systems.
Curious about the full range of peptide-based tools driving this field? Check out the peptide research index for more on current advances. Peptide innovation in oncology is only getting faster — now’s the time to pay attention.
Related Reading
aMitochondrial-Derived Peptide MOTS-c Targets SLC7A11 to Preserve Spermatogenesis by Suppressing Ferroptosis.
News · Adv Sci (Weinh)INB(3)P: A Multi-Modal and Interpretable Co-Attention Framework Integrating Property-Aware Explanations and Memory-Bank Contrastive Fusion for Blood-Brain Barrier Penetrating Peptide Discovery.
News · J Adv ResBacterial terminal oxidase bo(3) as a primary respiratory target of cathelicidin peptide hc-cath against Acinetobacter baumannii.
For Research Use Only
All content published on Pushing Peptides is intended for educational and informational purposes only. The information provided is not intended as medical advice, diagnosis, or treatment. Peptides discussed in this article are research compounds and are not approved for human therapeutic use by the FDA or any other regulatory agency. All studies referenced involve animal models or in vitro research unless otherwise stated. Consult a qualified healthcare professional before making any decisions related to your health. Pushing Peptides does not sell peptides — we are a vendor directory and educational resource.